<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152837</url>
  </required_header>
  <id_info>
    <org_study_id>PA-ADPKD-303</org_study_id>
    <nct_id>NCT04152837</nct_id>
  </id_info>
  <brief_title>Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease</brief_title>
  <acronym>ALERT</acronym>
  <official_title>An Open-Label Study of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Previously Experienced Abnormal Liver Chemistry Test Results While Receiving Tolvaptan: The ALERT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palladio Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palladio Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver&#xD;
      safety, and efficacy in subjects who previously experienced liver chemistry test&#xD;
      abnormalities while treated with tolvaptan and were permanently discontinued from the drug&#xD;
      for that reason. Up to 50 eligible subjects will be enrolled and treated with lixivaptan for&#xD;
      52 weeks following titration to an optimal dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver&#xD;
      safety, and efficacy in subjects who previously experienced liver chemistry test&#xD;
      abnormalities while treated with tolvaptan and were permanently discontinued from the drug&#xD;
      for that reason. Up to 50 subjects will be enrolled. Evaluations will include frequent&#xD;
      testing of liver chemistry (every week during the Baseline and Titration Periods and every 4&#xD;
      weeks during the Maintenance Period), physical examinations, vital signs, safety labs (serum&#xD;
      chemistry, hematology, urinalysis), estimated glomerular filtration rate (eGFR), urine&#xD;
      specific gravity and osmolality determinations and trough serum concentration of lixivaptan.&#xD;
      After meeting entry criteria during a 1-3 week Screening Period that can extend up to 8 weeks&#xD;
      for medication adjustment, subjects will enter a 3 week no study treatment Baseline Period to&#xD;
      obtain baseline measurements followed by a 3-6 week Titration Period during which lixivaptan&#xD;
      administered twice daily (BID) will be titrated to a dose that is tolerated and results in a&#xD;
      reduced trough urine specific gravity (or the maximum dose level). The minimum dose to enter&#xD;
      the Maintenance Period is 100 mg BID. Treatment will continue for up to 52 weeks (12 months)&#xD;
      after which study drug will be held, and final assessments obtained during the Follow-up&#xD;
      Period of 4 weeks. The total study duration will be up to approximately 73 weeks (16.8&#xD;
      months).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, single treatment group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abnormal ALT Values</measure>
    <time_frame>52 weeks</time_frame>
    <description>Proportion of subjects who develop alanine aminotransferase (ALT) levels &gt;3 x ULN adjudicated to be related to lixivaptan and resulted in discontinuation of the study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects reporting at least one adverse event</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number and percent of subjects who develop at least 1 adverse event during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Total Bilirubin Values</measure>
    <time_frame>52 weeks</time_frame>
    <description>Proportion of subjects who develop total bilirubin levels &gt;2 x ULN during treatment with lixivaptan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in estimated glomerular filtration rate (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (SBP)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Sodium Concentration</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in serum sodium concentration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Polycystic Kidney Disease, Adult</condition>
  <arm_group>
    <arm_group_label>Lixivaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lixivaptan oral capsules, 100-200 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixivaptan</intervention_name>
    <description>Oral vasopressin V2 antagonist</description>
    <arm_group_label>Lixivaptan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, between 18 and 65 years of age (inclusive) at the time of Screening.&#xD;
&#xD;
          -  Documented diagnosis of ADPKD by imaging or genetic analysis previously treated with&#xD;
             tolvaptan for that indication.&#xD;
&#xD;
          -  Baseline eGFR &gt; 20 ml/min/1.73 m2.&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 35 kg/m2 (inclusive) at the time of Screening.&#xD;
&#xD;
          -  Documented history of:&#xD;
&#xD;
               -  At least 2 elevated alanine aminotransferase (ALT) levels, 1 ALT level &gt;2 times&#xD;
                  (x) the upper limit of normal (ULN) and 1 ALT level &gt;3 x ULN while the subject&#xD;
                  was receiving tolvaptan, or within 4 weeks after tolvaptan discontinuation, with&#xD;
                  no other explanation for the ALT elevations. The 2 elevated ALT measurements&#xD;
                  could be recorded during the same instance of liver injury or during distinct&#xD;
                  instances; OR&#xD;
&#xD;
               -  At least 2 elevated ALT levels, 1 ALT level &gt;2 x the subject's stable baseline&#xD;
                  level and 1 ALT level &gt;3 x the subject's stable baseline level while the subject&#xD;
                  was receiving tolvaptan, or within 4 weeks after tolvaptan discontinuation, with&#xD;
                  no other explanation for the ALT elevations; provided that at least one ALT&#xD;
                  elevation was &gt;2 x ULN. The 2 elevated ALT measurements could be recorded during&#xD;
                  the same instance of liver injury or during distinct instances; OR&#xD;
&#xD;
               -  A pattern of ALT elevations deemed by the Investigator to be consistent with&#xD;
                  tolvaptan liver injury with no other explanation for the ALT elevations and&#xD;
                  agreement of the medical monitor and sponsor.&#xD;
&#xD;
          -  Permanent discontinuation of tolvaptan because of the ALT abnormality.&#xD;
&#xD;
          -  If re-challenge with tolvaptan was performed, the ALT level must have increased to &gt;2&#xD;
             x ULN upon rechallenge or the ALT level was increasing but tolvaptan was stopped for&#xD;
             patient safety reasons before it reached &gt; 2 x ULN after having previously normalized.&#xD;
&#xD;
          -  Appropriate control of hypertension including an angiotensin converting enzyme&#xD;
             inhibitor or angiotensin receptor blocker (unless not considered appropriate for the&#xD;
             subject) without the use of a diuretic in concert with Kidney Disease: Improving&#xD;
             Global Outcomes (KDIGO) &quot;Clinical Practice Guideline for the Management of Blood&#xD;
             Pressure in Chronic Kidney Disease&quot;.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known sensitivity or idiosyncratic reaction to any compound present in lixivaptan and&#xD;
             related compounds.&#xD;
&#xD;
          -  Hypovolemia or inability to perceive thirst&#xD;
&#xD;
          -  Subjects who are taking, have taken within the past 2 weeks, or are expected to be&#xD;
             taking, strong or moderate CYP3A4 or CYP2C8 inhibitors or inducers including regular&#xD;
             use of grapefruit juice, Seville oranges, or St. John's wort.&#xD;
&#xD;
          -  Prior use of tolvaptan within the past 3 months or until a previously elevated ALT&#xD;
             level has returned to â‰¤1 x ULN.&#xD;
&#xD;
          -  Prior use of conivaptan, somatostatin analogs (e.g., lanreotide, pasireotide,&#xD;
             octreotide, etc.), metformin, nicotinamide, bardoxolone, venglustat, demeclocycline,&#xD;
             or mammalian Target of Rapamycin (mTOR) kinase inhibitors (e.g., everolimus,&#xD;
             sirolimus, etc.) to treat ADPKD within the past 3 months&#xD;
&#xD;
          -  Requirement for chronic diuretic use&#xD;
&#xD;
          -  Advanced diabetes (e.g., glycosylated hemoglobin [HgbA1c] &gt;7.5%, and/or glycosuria by&#xD;
             dipstick, significant proteinuria [&gt;300 mcg albumin/mg creatinine]), other significant&#xD;
             renal disease, transplanted kidney, recent kidney surgery within the past 6 months&#xD;
             (including cyst drainage or fenestration) or acute kidney injury within past 6 months&#xD;
&#xD;
          -  Clinically significant incontinence, overactive bladder, or urinary retention (e.g.,&#xD;
             benign prostatic hyperplasia).&#xD;
&#xD;
          -  New York Heart Association Functional Class 3 or 4 heart failure or other significant&#xD;
             cardiac or electrocardiogram (ECG) findings that could pose a safety risk to the&#xD;
             subject.&#xD;
&#xD;
          -  Clinically significant liver disease or impairment or active chronic hepatitis at&#xD;
             Screening.&#xD;
&#xD;
          -  Elevated baseline levels of serum ALT or total bilirubin.&#xD;
&#xD;
          -  History of drug or alcohol abuse in the past 2 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Neil Shusterman, MD</last_name>
    <phone>267-609-7553</phone>
    <email>ClinicalTrials@palladiobio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Waymer</last_name>
    <phone>267-609-7553</phone>
    <email>ClinicalTrials@palladiobio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Bottomlee</last_name>
      <email>amybottomlee@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Michal Mrug, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XiaoXiao Yin</last_name>
      <email>XiaoxiaoYin@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Anjay Rastogi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine &amp; Biological Sciences</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serdar Aydin, MD</last_name>
      <email>serdarmd@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Arlene Chapman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charalett Diggs</last_name>
      <email>charalett.diggs@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Seliger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Clair Nephrology</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemarie Henschel</last_name>
      <phone>313-432-6273</phone>
      <email>RHenschel@scsp.net</email>
    </contact>
    <investigator>
      <last_name>Marjana Dimitrijevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Leistikow</last_name>
      <email>leistikow.kathleen@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Vicente Torres, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brookview Hills Research Associates, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Vanhoy</last_name>
      <phone>336-245-6320</phone>
      <email>CVanhoy@brookviewhills.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Greenwood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research Center, LLC</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Hanzl</last_name>
      <email>steph.hanzl@necresearch.org</email>
    </contact>
    <investigator>
      <last_name>Nelson Kopyt, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates of Northern Virginia, Inc.</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Musirah Khan</last_name>
      <phone>703-961-0565</phone>
      <phone_ext>224</phone_ext>
      <email>musirah.khan@nanvonline.com</email>
    </contact>
    <investigator>
      <last_name>Amadshah Mirkhel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

